

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**PASSING OF CONSISTENCY EVALUATION FOR**  
**“LINEZOLID AND GLUCOSE INJECTION”**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Linezolid and Glucose Injection” (brand name: Yi Rui Da (易瑞達)) (specifications: 100ml and 300ml), an anti-infectious drug of the Group, has obtained the notice of approval of supplemental applications issued by the National Medical Products Administration of the People’s Republic of China, and has passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs (the “**Consistency Evaluation**”), being one of the first batch of its kind to pass the Consistency Evaluation in China.

Linezolid and Glucose Injection is an oxazolidinone antibacterial drug, which is mainly used for the empirical treatment of G+ bacterial infections. With the characteristics of unique mechanism, high penetration rate, broad antibacterial spectrum and high safety, it is widely used in respiratory, blood, intensive care units (ICU), tuberculosis/infection and other departments. Linezolid and Glucose Injection is included in the 2020 National Drugs Catalogue for Medical Insurance, and recommended by authoritative guidelines such as “HAP/VAP Diagnosis and Treatment Guidelines (2018)” and “Consensus on Treatment of Linezolid Anti-tuberculosis” of the Chinese Medical Association, and the “Guidelines for the Treatment of Drug-Resistant Tuberculosis” of the World Health Organization (WHO) as the first-line drug for empirical treatment of G+ bacterial infections. The passing of the Consistency Evaluation can further benefit the market expansion of Yi Rui Da.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 7 January 2021

*As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Li Kwok Tung Donald.*